More Americans have received at least 1 dose of a coronavirus disease 2019 (COVID-19) vaccine than have tested positive for the virus; Biden administration funds mass production of a rapid over-the-counter COVID-19 test; breast cancer surpasses lung cancer as most common cancer worldwide.
Reported by Bloomberg, the United States reached a milestone yesterday as more Americans have received at least 1 dose of a vaccine against coronavirus disease 2019 (COVID-19) than have tested positive for the virus. While vaccine rollout has been fragmented at the state level, the United States has been administering vaccine shots at a faster rate than any country worldwide, with 26.5 million Americans having received 1 or both doses of an available COVID-19 vaccine. Since the first US case of coronavirus was reported on January 20, 2020, 26.3 million people nationwide have tested positive.
Yesterday, the Biden administration announced they will be funding the mass production of a rapid, over-the-counter COVID-19 test designed by Australian company Ellume, which had received authorization for the test in December. Reported by The Hill, Ellume will receive nearly $232 million to manufacture the tests, adding to the $30 million it received from the National Institutes of Health's RADx initiative. The United States will additionally fund an American manufacturing facility, in which the company will be able to produce up to 19 million tests per month at full capacity.
Reported by Reuters, the World Health Organization announced today that breast cancer (BC) has surpassed lung cancer as the most common form of cancer worldwide. Last year, an estimated 2.3 million new cases of BC were diagnosed, representing 11.7% of all cancer cases. After being the most common type of cancer for the last 2 decades, lung cancer is now second, followed by colorectal cancer as third most widespread. Notably, cancer is expected to become more common as the global population grows and life expectancy increases, with approximately 30 million new cases projected per year in 2040 compared with 19.3 million in 2020.
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
Considerations for Immunotherapy Duration in NSCLC: Dr Heather Wakelee
September 11th 2024Heather Wakelee, MD, Stanford University, discusses the pros and cons of different durations of immunotherapy in non-small cell lung cancer (NSCLC) and the future outlook for patient-specific care.
Read More
Dr Sandip Patel Previews the Highly Anticipated 50th Anniversary of WCLC
September 6th 2024The 2024 World Conference on Lung Cancer (WCLC) marks the 50th anniversary of the International Association for the Study of Lung Cancer. Sandip Patel, MD, joined for an interview looking forward to the unique features of this year's meeting.
Read More